Form 8-K - Current report:
SEC Accession No. 0001628280-20-009081
Filing Date
2020-06-05
Accepted
2020-06-05 16:17:19
Documents
6
Period of Report
2020-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K oysterpoint-8xkxannual.htm 8-K 37985
2 image01.jpg GRAPHIC 123
3 image11.jpg GRAPHIC 123
4 image21.jpg GRAPHIC 123
5 image31.jpg GRAPHIC 123
6 image41.jpg GRAPHIC 123
  Complete submission text file 0001628280-20-009081.txt   40512
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 20946523
SIC: 2836 Biological Products, (No Diagnostic Substances)